Obizur is indicated to treat bleeding episodes in adult patients with acquired haemophilia caused by antibodies to Factor VIII (FVIII), a life-threatening acute bleeding disorder. It will allow
The trial, called GBM Agile, will test various treatments depending on the molecular profile of a patient’s tumor. Treatments that do not work will be dropped from the
SCY-078 is being developed as both an oral and IV formulation to treat invasive and life-threatening fungal infections including candidemia and invasive aspergillosis. The study will assess the
Of the total amount, the company will spend €5bn for preclinical research through 2020, and €1.5bn will go to collaborations with external partners. The move is intended to
The drug can now be used in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection and in patients co-infected with human immunodeficiency virus
AxioMx develops recombinant antibody technologies. The company offers a range of custom antibody discovery and development services for the research, diagnostic and therapeutic marketplaces. Abcam will pay $20m
The company will interpret samples in rare disease and cancer as part of the project, which is being undertaken by Genomics England. The project intends to sequence 100,000
The deal extends Recipharm’s existing contract to manufacture the API until 2025. Under the new deal, Daewoong will annually purchase minimum API quantities of Erdosteine worth about €25m
The partnership is based around Enterome’s metagenomic technology platform that offers an insight of the gut microbiome composition. The composition plays an important role in identifying how effective
Thetanix is designed to treat paediatric Crohn’s disease (PCD), which is a chronic inflammatory bowel disease that causes inflammation, or swelling, across the lining of the digestive tract,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.